ICU Medical experienced a 6.3% revenue decline in fiscal 2025, driven notably by increased tariffs on critical medical device imports and the transition of its IV Solutions business into a joint venture with Otsuka. Although operating income remained stable year-over-year, net income swung from loss to near-breakeven reflecting cost controls and prepayments on debt funded by divestiture proceeds. The company’s extensive product portfolio and recent acquisitions underpin its moat, but tariff uncertainty and FDA regulatory scrutiny pose ongoing operational risks. Capital expenditures are set to increase moderately in 2026, focusing on manufacturing facilities and product placement, while debt refinancing reduces near-term principal repayments.